Navigation Links
AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
Date:4/22/2009

QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer. The poster was presented at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado.

The poster (#5567) entitled, "Phase I dose-escalation, safety, and pharmacokinetic study on weekly oral AEZS-112, a small molecule anti-cancer agent in patients with advanced cancer and lymphoma", D.W. Northfelt, reviewed results of this Phase I study designed to evaluate the safety, tolerability and pharmacokinetics of ascending doses of AEZS-112 in patients with the above-mentioned forms of cancer.

Results

In part I, 22 patients (12 men/10 women) were studied on 7 dose levels ranging from 13 to 800 mg/week. In all, 62 treatment cycles were administered. In part II, 22 patients (12 men/10 women) were studied on 5-dose levels ranging from 120 to 600 (=200x3) mg/week. As of April 1, 2009, 62 treatment cycles were administered (mean 3.2/patient); treatment was ongoing in 8 patients. Stable disease (SD) for more than 12 weeks was observed in 16 patients; 4 more patients were ongoing at less than 12 weeks. Prolonged courses of SD ranging from 20 to 39+ weeks were observed in 9 patients with the following primary cancer types: trachea (39+), tongue (30+), thyroid (29+), prostate and melanoma (28), non-small cell lung cancer (26+), pancreas and 2x colorectal (20).

Except for one patient with a background of gastrointestinal problems (GI) who had dose-limiting GI reactions a
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According to a new ... the global orthobiologics market was valued at USD 3,754.6 million ... USD 5,519.9million in 2019at a CAGR of 5.9% from 2013 ... years and above is afflicted by bone and joint disorders, ... year 2020. This has and will continue to increase the ...
(Date:8/29/2014)... Livermore, California (PRWEB) August 29, 2014 ... Department of Energy's 2014 Hydrogen Production R&D ... photoelectrochemically -- by splitting water using sunlight. , ... Laboratory (NREL) and the University of Nevada, Las ... its work developing models of photoelectrochemical solar-hydrogen production ...
(Date:8/28/2014)... SPIE Fellow Glenn Boreman, Professor and ... and Director of the Center for Optoelectronics and Optical ... and co-founder and Chairman of the Board of Plasmonics, ... Vice President of SPIE, the international society for optics ... recent election results at the Annual General Meeting of ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... an organizational meeting last week to name its leadership. ... Wisconsin institutions. , ,Tom Hefty, former co-chairman of the ... of directors. He is now with law firm Reinhart, ... dean of the UW-Madison College of Engineering , ...
... information officers made the Computerworld magazine's top-100 list this year. ... Manufacturing Co. , in Racine. Modine specializes in thermal management ... London and a carbon-dioxide-cooled Jeep, and has been active in ... CIO of ShopKo Stores Inc. , in Green Bay. ...
... Wis. The invention of three Medical College ... patients' brains. Kyron Clinical Imaging Inc. received FDA clearance ... the Milwaukee Journal-Sentinel reported . , ,Kyron's software would ... MRI, scanner. A sample image released by the company ...
Cached Biology Technology:
(Date:8/31/2014)... new study, published today in Nature Climate Change , ... alone will reach, if not exceed, the global targets for ... study,s authors say we should all think carefully about the ... healthier diets across the world is just one of a ... dangerous climate change and ensure there is enough food for ...
(Date:8/31/2014)... in French . ... in the prestigious Nature Neuroscience journal by, Sylvain ... the Douglas Mental Health University Institute and McGill University, opens ... dynamic mechanisms controlling memory as well of the role of ... the subiculum. , In 2009, they developed a unique ...
(Date:8/29/2014)... 2014) Scientists at the Barshop Institute for Longevity ... at the UT Health Science Center at San Antonio, ... of the longest-lived rodent, the naked mole rat. ... of naked mole rats protects and alters the activity ... obsolete proteins. , The factor also protects proteasome function ...
Breaking Biology News(10 mins):Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2Factor in naked mole rat's cells enhances protein integrity 2
... preterm infants may not be fully protected against invasitve ... The findings are reported in the November issue of ... The study, conducted by researchers from Newcastle University, began ... The survey found that preterm infants at increased risk ...
... Four researchers at the U.S. Department of ... have been awarded a total of 65 million ... Gene/P ("Intrepid") supercomputer. The researchers will conduct advanced ... be almost impossible and impractical in the natural ...
... VA Age-related hearing loss (ARHL), one of the four ... low serum levels of folic acid, according to new research ... Head and Neck Surgery . Hearing loss is ... million Americans between the ages of 60 and 74 dealing ...
Cached Biology News:Argonne scientists awarded supercomputing time to enable scientific breakthroughs 2Argonne scientists awarded supercomputing time to enable scientific breakthroughs 3Argonne scientists awarded supercomputing time to enable scientific breakthroughs 4
BOND ELUT MATRIX-C18, 25 mg ...
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Biology Products: